Michael R. Green

A novel KIR3DL2-directed CAR T-cell therapy for cutaneous and systemic T-cell lymphomas

This paper develops a KIR3DL2-directed CAR T-cell therapy for T-cell lymphomas, showing preclinical efficacy and safety in xenograft models.

A Bivalent Molecular Glue Linking Lysine Acetyltransferases to Oncogene-induced Cell Death

This paper develops KAT-TCIPs to induce cell death in diffuse large B cell lymphoma by redirecting p300 and CBP to activate programmed cell death genes repressed by BCL6.

Signaling induced biophysical disruption of repressed chromatin domains drives immune cell fate

The paper identifies H3 serine 28 phosphorylation as a mechanism driving chromatin derepression and immune cell fate transitions by disrupting repressive chromatin domains.

Clonal hematopoiesis is associated with increased toxicity in large B-cell lymphoma patients treated with chimeric antigen receptor T cell therapy

This study finds that clonal hematopoiesis mutations, particularly in DNMT3A, TET2, and ASXL1, are linked to increased toxicity in patients undergoing anti-CD19 CAR T-cell therapy for large B-cell lymphoma.

Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma

This study identifies subtype-specific and co-occurring genetic alterations across major B-NHL subtypes using targeted sequencing of 380 genes in 685 tumors.